Hungarian Multicenter Non-Interventional Study of Continued Avastin (Bevacizumab) Plus Chemotherapy Until First Progression Following Induction Treatment With Chemotherapy Doublet Plus Avastin in First Line Treatment of Patients With Metastatic Colorectal Carcinoma

Trial Profile

Hungarian Multicenter Non-Interventional Study of Continued Avastin (Bevacizumab) Plus Chemotherapy Until First Progression Following Induction Treatment With Chemotherapy Doublet Plus Avastin in First Line Treatment of Patients With Metastatic Colorectal Carcinoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms AVACONT
  • Sponsors Roche
  • Most Recent Events

    • 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Sep 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2017.
    • 01 Sep 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top